Date Title Description PDF
02 Mar 2021 On business and financial situation The Company releases a presentation related to an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States  Download
24 Feb 2021 About corporate governance The Company informs about the agreements adopted by the Board of Directors  Download
27 Nov 2020 On business and financial situation The Company publishes the results of the PRISMA-3 study of the efficacy and safety of Doria® in schizophrenic patients in the journal npj Schizophrenia Download
09 Jul 2020 On business and financial situation ROVI informs on the Collaboration with Moderna for Outside the United States Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate Download

Pages

Date Title Description PDF
29 Mar 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted on 28 March 2022 and end of the share buyback program Download
28 Mar 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 21 March 2022 and 25 March 2022 Download
21 Mar 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 14 March 2022 and 18 March 2022 Download
14 Mar 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 7 March 2022 and 11 March 2022 Download
07 Mar 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 28 February 2022 and 4 March 2022 Download

Pages

Date Title Description PDF
21 Feb 2012 Información sobre resultados (2) Download
21 Feb 2012 Información sobre resultados Download
21 Feb 2012 Informe Anual de Gobierno Corporativo Download
15 Feb 2012 Cambios en política de inversión, áreas de negocio y líneas de productos Download
22 Dec 2011 Composición del Consejo de Administración Download

Pages